"The big line of brand generic drugs also brings opportunities for Chinese companies。"Yu Mingde, chairman of the China Medical Enterprise Management Association, introduced the global generic drug and opportunity forum held on November 17，In the past 5 years，In the United States, there are patent drugs with sales revenue of $ 82 billion in the United States.，Chinese companies should seize this opportunity。
 
At present, the global new drug research and development is stagnant，A large amount of patented medicine is about to expire，Even if the original pharmaceutical manufacturer has an advantage in price，But with the emergence of a large number of brand generic drugs，The original research medicine has no longer the scenery，Global generic drugs have entered the brand era。Local enterprises should develop vigorously developing specialized brands，Road to imitate creation。Although there are many opportunities for local companies，But the multinational company is also expanding its own generic drug business，Most multinational companies that are mainly research stake online sports bettingdrugs My stake betting apphave their own generic drug brands。In addition，Some companies also acquire some good generic products to enrich their product lines。
 
　　Stake Sports Betting
 
According to statistics，to 2012，There will be a patented drug of $ 139 billion in patent protection，In this case，Many international large pharmaceutical companies decide to enter the field of generic drugs，Since the R & D speed of many companies cannot keep up with market changes，So the brand of generic drugs developed，To establish a new business model。Some experts think，This is not just a problem with R & D，Research indicates，Under the financial crisis，Since governments of various countries are compressed medical expenses，Therefore, generic drugs have better development prospects。In addition，multinational pharmaceutical companies are facing great pressure: one，Headquarters has high expectations for the Chinese market，Many companies directly put the headquarters of the Asia -Pacific region in China，Because the Chinese market occupies an increasingly important position in the business of multinational companies;，The Chinese market occupies a larger share in the profits of foreign pharmaceutical companies，These companies also discovered，The growth of product lines in other parts of the world can no longer meet the expectations of company growth。Therefore，The attention points of these companies have been transferred to brand generic drugs、Vaccine and OTC products。
 
Current medicines on the market can be divided into: innovative medicine、Original Research Medicine、Brand imitation medicine、Non -branded generic drugs。From the composite growth rate of these types of products for nearly 4 years，Products of foreign companies account for 95%of patented drugs to grow slower，The growth rate in 2005 was 5%、2006 growth rate was 6%、The growth rate in 2007 was stake online sports betting7%，Founded in 2008。The growth My stake betting apprate of brand generic drugs is the fastest，From 2005 to 2008，Keep a growth rate of more than 40%。The price of not brand generic drugs is getting worse，The growth rate in 2005 was 19%、The growth rate in 2006 was 17%、The growth rate in 2007 was 16%、The growth rate in 2008 was 16%。
 
According to an expert introduction，The advantages of the original research drug expired patent have become weaker and weaker。In China，The price of the original research medicine is 4 times the price of other products，gross profit margin and quantity are 5 times the number of other companies。If it is not so high profit support，Foreign companies cannot occupy 30%of China's market share。This is different from the situation in the United States，Many original medicines have been patented after the patent period，Even if the price does not fall，gross profit margin will also decrease significantly。And the original pricing treatment of the original drug in China will not last long，With the disappearance of separate pricing policies，The trend of the transformation of foreign companies to brand generic drugs is very obvious。
 
　　domestic enterprises: based on the specialty of the specialized innovation
 
In recent years，The high prices of the original research drugs of foreign companies are often equivalent to high quality，Even many people in the industry think，The high quality of the original research drugs of foreign companies allows them to pay a higher price。In the eyes of experts，Foreign companies can gain advantages in the Chinese market，does not depend on quality。Actually，Under a separate pricing policy，The advantage of foreign companies is high profits，Have the ability to do more marketing such as academic promotion，to affect the "pen" in the doctor's hands。And domestic generic drug companies have low profits，No ability to carry out large -scale marketing activities。and marketing activities is the process stake betting appof making non -brand generic drugs stake online sports bettinginto brand generic drugs。
 
According to an introduction，After the name of OTC drug products was canceled in 2006，Creating brand generic drugs is difficult to get difficult for local enterprises。Former generic drugs can have their own brand，Even the same ingredients can have different names。Since SFDA's implementation of common drug management，This era of "brand game" is over。But from another perspective，Regardless of whether there is a brand，These companies are in market competition，Therefore，Enterprises need to build an advantage in the field of specialty，So as to create a brand in a limited field。 　　

    If in the field of Chinese tumor，The price of non -branded drugs in China is almost the same as the price of the original research medicine。This description: First，Quality differences cannot explain the difference in quantity; second，Quality is no longer the most important influencing factor，The role of brand promotion will become more and more important; third，In the existing price system，Local enterprises can make breakthroughs in the field of specialty and biotechnology drugs，But in the field of basic medicine，The opportunity for brand promotion is getting less and less，More than a dozen companies that can do something。
 
Experts point out，In the generic drug market，Be sure to dig unique products for imitation，Make yourself a "oligopoly" generic drug in the field of specialty。According to the reporter's understanding，Haizheng Pharmaceutical, which is currently leading in the field of tumors in China, has its own oligarchy。
 
Research indicates，The competitive intensity determines the performance of generic drugs。According to relevant statistics,，A product of 2 to 4 brands in a certain compound，Its compound growth rate is 28%; when there are 5 to 7 brand products，Compound growth rate is 29%，When it exceeds 7，Its compound growth rate is only 15%。The average stake sports betting appcompound stake online sports bettinggrowth rate of generic drugs is 19%。From this can be judged，When there are less than 7 competing products，Enterprises will get better returns。Compounds with 7 brand products in this market only account for 16%of all statistical products，Among the 20,000 products of a total of 1,500 companies in total，There are more than 3,000 oligoral drugs，These products account for 30%of all statistical products sales。
 
So，Facing the blue ocean brought by 3000 varieties，Local enterprises have sufficient opportunities to make breakthroughs in the field of specialty。Expert reminder，The time from oligarch to bulls is 3 to 5 years，Enterprises that manufacture oligopoly generic drugs must grasp the dynamic management of the product line，Make sure that new generic drugs can be launched every year。
 
and after 3 to 5 years，The oligopoly market of generic drugs will move towards bulls。